We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

This study has been terminated.
(Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01685255
First Posted: September 14, 2012
Last Update Posted: June 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Incyte Corporation
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 23, 2014
  Primary Completion Date: October 23, 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Submission: November 4, 2015